Latest News

Teva Reports Second Quarter 2022 Financial Results

Teva Reports Second Quarter 2022 Financial Results

Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims

Teva Reaches Agreement With San Francisco to Settle Opioid-Related Claims

Teva Announces Appointment of New Global R&D and Chief Medical Officer

Teva Announces Appointment of New Global R&D and Chief Medical Officer

Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 2...

Teva to Host Conference Call to Discuss Second Quarter 2022 Financial Results at 8 a.m. ET on July 27, 20

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezu...

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY® (fremanezumab)

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

Teva Announces Settlement with Aurobindo Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Pr...

New Real-World Data Evaluating AJOVY® (fremanezumab-vfrm) Injection Use in Patients With Migraine Present

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache So...

Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Part...

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner t

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric As...

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Associa

Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissol...

Teva Issues Voluntary Nationwide Recall of One Lot of Anagrelide Capsules, USP 0.5 mg Due to Dissolution Test Failure

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Associatio...

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Ann

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalat...

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation P